ledipasvir/sofosbuvir
Sign in to saveAlso known as harvoni
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. Some evidence also supports use in HCV genotype 3 and 4. It is taken daily by mouth for 8–24 weeks.
Medication
- Brand names
- Harvoni
- Drug class
- Antivirals for treatment of HCV infections
- Active ingredients
- sofosbuvir, ledipasvir, ledipasvir / sofosbuvir
- Dosage form
- Oral Tablet, Oral Pellet
Clinical Trials
85 registered- PHASE2COMPLETEDSofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal InsufficiencyGilead Sciences · NCT01958281
- PHASE3COMPLETEDSafety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)Gilead Sciences · NCT01851330
- PHASE4WITHDRAWNLedipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.Kaiser Permanente · NCT03279133
- COMPLETEDA Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseGilead Sciences · NCT01457768
- PHASE2COMPLETEDLedipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell DiseaseGilead Sciences · NCT02301936
- PHASE2COMPLETEDLedipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver TransplantGilead Sciences · NCT01938430
~8 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Resistance
- NS5A mutations
- NS5B mutations
- Cross resistance
- Side effects
- Drug interactions
- Mechanisms of action
- Pharmacokinetics
- Elimination
- Blood detection
- Society and culture
- References
- External links
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. Some evidence also supports use in HCV genotype 3 and 4. It is taken daily by mouth for 8–24 weeks.
It is generally well tolerated. Common side effects include muscle pains, headache, nausea, rash, and cough. It is unclear if use in pregnancy is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B polymerase.
Excerpted from Wikipedia’s “ledipasvir/sofosbuvir” article, available under the CC BY-SA 4.0 licence.